Compare UFG & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | LIXT |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Singapore | United States |
| Employees | 17 | 4 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 25.3M |
| IPO Year | N/A | N/A |
| Metric | UFG | LIXT |
|---|---|---|
| Price | $0.85 | $3.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 249.9K | 38.1K |
| Earning Date | 04-22-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.40 | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.64 |
| 52 Week High | $9.91 | $6.09 |
| Indicator | UFG | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 55.83 |
| Support Level | $0.78 | $2.97 |
| Resistance Level | $1.29 | $3.30 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 29.64 | 80.88 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.